Viridian Therapeutics Inc (NASDAQ: VRDN) flaunted slowness of -3.07% at $19.24, before settling in for the price of $19.85 at the close. Taking a more long-term approach, VRDN posted a 52-week range of $11.40-$27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -4.19%. Meanwhile, its Annual Earning per share during the time was 20.35%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.77%. This publicly-traded company’s shares outstanding now amounts to $79.18 million, simultaneously with a float of $70.50 million. The organization now has a market capitalization sitting at $1.52 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.42, while the 200-day Moving Average is $17.60.
Viridian Therapeutics Inc (VRDN) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Viridian Therapeutics Inc industry. Viridian Therapeutics Inc’s current insider ownership accounts for 11.00%, in contrast to 99.20% institutional ownership. According to the most recent insider trade that took place on Sep 27 ’24, this organization’s Chief Operating Officer bought 5,000 shares at the rate of 23.41, making the entire transaction reach 117,050 in total value, affecting insider ownership by 6,000. Preceding that transaction, on Sep 27 ’24, Company’s President and CEO bought 21,400 for 23.33, making the whole transaction’s value amount to 499,262. This particular insider is now the holder of 21,400 in total.
Viridian Therapeutics Inc (VRDN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.
Viridian Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 23.77% and is forecasted to reach -4.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.47% through the next 5 years, which can be compared against the 20.35% growth it accomplished over the previous five years trading on the market.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Let’s observe the current performance indicators for Viridian Therapeutics Inc (VRDN). It’s Quick Ratio in the last reported quarter now stands at 18.55. The Stock has managed to achieve an average true range (ATR) of 1.07. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5080.17.
In the same vein, VRDN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.31, a figure that is expected to reach -1.04 in the next quarter, and analysts are predicting that it will be -4.16 at the market close of one year from today.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Now, what If we examine the latest scores posted by [Viridian Therapeutics Inc, VRDN]. During the last 5-days, its volume was lower the volume of 1.23 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 61.20% While, its Average True Range was 1.04.
Raw Stochastic average of Viridian Therapeutics Inc (VRDN) in the period of the previous 100 days is set at 24.91%, which indicates a major fall in contrast to 67.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 41.00% that was lower than 62.60% volatility it exhibited in the past 100-days period.
